Oxford Cannabinoid Holdings Plc is the holding company of Oxford Cannabinoid Technologies Ltd, a UK-based pharmaceutical company, which uses cutting-edge technology and a drug development strategy to explore the potential of cannabinoid derivatives, phytocannabinoids, and other drug candidates on the endocannabinoid system, and bring pioneering treatments to market. OCT believes it is important to develop a deeper understanding of the molecular actions of cannabinoids. We manage a wide-ranging research program that investigates the medical potential of cannabinoids across different therapeutic areas, with a particular focus on pain. By employing the latest scientific techniques to provide more evidence that supports the positive effects of cannabinoids, it is our vision to become a global leader in developing cannabinoid-based prescription medication, improving the quality of life for millions of patients.